Letters to the Editor

T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines

Department of Hematology, Leiden UMC, Leiden
Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam
Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam
Department of Hematology, Leiden UMC, Leiden
Department of Hematology, Leiden UMC, Leiden
Department of Hematology, Leiden UMC, Leiden
Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam
Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam
Department of Hematology, Amsterdam UMC location Vrije Universiteit, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam UMC, Amsterdam
Department of Hematology, Leiden UMC, Leiden
Department of Hematology, Leiden UMC, Leiden
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam
Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen
Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven, the Netherlands; Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboudumc, Nijmegen
Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven
Department of Epidemiology and Data Science, Amsterdam UMC location Vrije Universiteit, Amsterdam
Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam UMC, Amsterdam
Centre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven
Department of Laboratory Medicine, Central Diagnostic Laboratory, Amsterdam UMC, Amsterdam
Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Department of Laboratory Medicine, Laboratory for Specialized Diagnostics and Research, Laboratory Medical Immunology, Amsterdam UMC, Amsterdam
Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Department of Laboratory Medicine, Laboratory for Specialized Diagnostics and Research, Laboratory Medical Immunology, Amsterdam UMC, Amsterdam
Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam
Netherlands Comprehensive Cancer Organisation, Utrecht
Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen
Department of Viroscience, Erasmus University Medical Center, Rotterdam
Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam
Department of Infectious Diseases, Amsterdam UMC location University of Amsterdam, Amsterdam
Department of Hematology, Amsterdam UMC location Vrije Universiteit, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; Department of Internal Medicine-Hematology, St. Antonius Hospital, Nieuwegein
Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; Department of Hematopoiesis, Sanquin Research, Amsterdam
Department of Hematology, Leiden UMC, Leiden
Department of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam
Iris Kant, Thecla Graas, Belle Toussaint, Sterre de Jong, Shahan Darwesh, Sandjiv Mahes, Dora Kamminga, Matthijs Koelewijn, Gino Faber, Guus Beaumont, Marije Engel, R. Cheyenne Pierie, Suzanne Janssen, Kazimierz Groen, Judith Burger, Joey Bouhuijs, Paul Baars, Marit van Gils, Edith van Dijkman, Jarom Heijmans, Yara Witte, Rogers Nahui Palomino, Said Omar, Sonja Zweegman, Caya van den Vegt, Ilonka Arends-Halbesma, Emma de Pater, Margriet Dijkstra, Nynke Rots, Esther Siteur-van Rijnstra, Dennis de Rooij, Rogier Sanders, Meliawati Poniman, Wouter Olijhoek, Jacqueline van Rijswijk, Tim Beaumont, Lusia Çetinel, Louis Schellekens, Yvonne den Hartogh, Jacqueline Cloos, Suzanne Weijers, Saïda Tonouh-Aajoud, Selime Avci, Elianne Roelandse-Koop, Willem Dik
Collaborative group: COBRA KAI study team (Iris Kant, Thecla Graas, Belle Toussaint, Sterre de Jong, Shahan Darwesh, Sandjiv Mahes, Dora Kamminga, Matthijs Koelewijn, Gino Faber, Guus Beaumont, Marije Engel, R. Cheyenne Pierie, Suzanne Janssen, Kazimierz Groen, Judith Burger, Joey Bouhuijs, Paul Baars, Marit van Gils, Edith van Dijkman, Jarom Heijmans, Yara Witte, Rogers Nahui Palomino, Said Omar, Sonja Zweegman, Caya van den Vegt, Ilonka Arends-Halbesma, Emma de Pater, Margriet Dijkstra, Nynke Rots, Esther Siteur-van Rijnstra, Dennis de Rooij, Rogier Sanders, Meliawati Poniman, Wouter Olijhoek, Jacqueline van Rijswijk, Tim Beaumont, Lusia Çetinel, Louis Schellekens, Yvonne den Hartogh, Jacqueline Cloos, Suzanne Weijers, Saïda Tonouh-Aajoud, Selime Avci, Elianne Roelandse-Koop, Willem Dik)
Haematologica Early view May 29, 2025 https://doi.org/10.3324/haematol.2024.287136